329006-50-0

Basic information

• Product Name: 1-O-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-5-O-allyl-2,3,4-tri-O-benzyl-D-ribitol
• Synonyms: 1-O-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-5-O-allyl-2,3,4-tri-O-benzyl-D-ribitol
• CAS NO: 329006-50-0
• Molecular Weight: 720.814
• Mol File: 329006-50-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-O-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-5-O-allyl-2,3,4-tri-O-benzyl-D-ribitol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-O-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-5-O-allyl-2,3,4-tri-O-benzyl-D-ribitol(329006-50-0)
• EPA Substance Registry System: 1-O-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-5-O-allyl-2,3,4-tri-O-benzyl-D-ribitol(329006-50-0)

Safety Data

• Hazardous Substances Data: 329006-50-0(Hazardous Substances Data)

Upstream product

• 111549-97-4 2,3,4-Tris-O-(phenylmethyl)-5-O-(prop-2-enyl)-D-ribitol 
• 13035-61-5 1,2,3,5-tetraacetylribose 

Downstream Products

• 111549-99-6 5-O-allyl-2,3,4-tri-O-benzyl-1-O-(β-D-ribofuranosyl)-D-ribitol 

Relevant articles and documents

Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them

The present invention relates to the field of the Medicine, in particular with the chemical synthesis of oligosaccharide mixtures derived of ribose-ribitol-phosphate, which are used as active principle in vaccines for the prevention of infections caused byHaemophilus influenzaetype b (Hib), as well as with the vaccines containing said oligosaccharide mixtures. The oligasaccharide mixtures obtained by chemical synthesis of the present invention, comprise repeating units of formulae (phosphate-ribosa-ribitol)n or (ribose-ribitol-phosphate)n of at least 5 compounds of structure A or B, which represent the repeating unit of the capsular polysaccharide ofHaemophilus influenzaetype b and differ only by n, being n a value contained between 4 and 25 (n≧4 y≦25), and wherein R1or R2is a spacer for conjugation to a carrier, with the condition of R1=spacer if R2=H, or R2=spacer if R1=H. The invention also is related with the immunogens containing such oligosaccharide mixtures, with the vaccines containing said immunogens and with the methods to prepare these oligosaccharides as mixtures. Furthermore, the invention includes the use of the vaccines, alone or combined with other vaccines, for the prevention of the infections caused byHaemophilus influenzaetype b.